58579-99-0

Upstream product

• 16618-56-7 2-chloro-1,5-dimethyl-3-nitro-benzene 
• 1635-84-3 2,4-Dimethyl-6-nitroanilin 
• 544-92-3 copper(I) cyanide 

Downstream Products

• 1044871-11-5 2-(4-(2-hydroxyethoxy)-3,5-dimethylphenyl)-5,7-dimethylquinazolin-4(3H)-one 
• 35490-78-9 2-amino-4,6-dimethyl-benzoic acid, methyl ester 
• 35562-53-9 Methyl-4.6-dimethyl-2-nitrobenzoat 
• 875241-52-4 2-amino-4,6-dimethyl benzamide 
• 35490-77-8 1-amino-2-cyano-3,5-dimethylbenzene 
• 860683-36-9 4,6-dimethyl-2-nitrobenzamide 

Relevant academic research and scientific papers

TREATMENT OF DISEASES BY EPIGENETIC REGULATION

The present disclosure provides non-naturally occurring polyphenol compounds that inhibit the bromodomain and extra terminal domain (BET) proteins. The disclosed compositions and methods can be used for treatment and prevention of cancer, including NUT midline carcinoma, Burkitt's Lymphoma, Acute Myelogenous Leukemia, and Multiple Myeloma; autoimmune or inflammatory diseases or conditions, and sepsis.

COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASES

The present disclosure relates to compounds, which are useful for regulating the expression of apolipoprotein A-I (ApoA-I), and their use for treatment and prevention of cardiovascular disease and related disease states, including cholesterol- or lipid-related disorders, such as, for example, atherosclerosis.